Polls Archive

Are you currently developing purification processes for antibody fragments?

  • Yes (58%)
  • No (42%)
  • Do you use both resins and membrane-based technology for chromatography?

    • Yes, we use both (56%)
    • We only use resins (43%)
    • We only use membranes (1%)
    • Does your organization leverage platform technologies for monoclonal antibody purification?

      • Yes (60%)
      • No (20%)
      • Not sure (20%)
      • To what extent has your organization adopted continuous chromatography?

        • We have fully adopted continuous chromatography  (24%)
        • We are currently implementing (10%)
        • We are currently considering (33%)
        • Not at all and not considering (33%)
        • To what extent has QbD been applied to your chromatography operations?

          • We apply it fully to all new processes (24%)
          • We have begun to apply to some processes (33%)
          • We are considering adopting QbD (43%)
          • We are not yet considering adopting QbD (0%)
           
           Page 1 of 2  1  2  »